# US 2026/0097027 A1 · Methods Of Treating Fabry Patients Having Renal Impairment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097027 A1
- Document ID: US20260097027A1
- Status: Published application
- Kind: A1
- Application number: 19/184,366
- Filed: 2025-04-21
- Published: 2026-04-09
- Earliest claimed: 2017-05-30
- Assignees: Amicus Therapeutics, Inc.
- Applicants: Amicus Therapeutics, Inc.
- Inventors: Jeff Castelli; Elfrida Benjamin
- Web page: https://patentgrep.com/patent/US20260097027A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 13/12: of the kidneys
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

## Claims

### Claim 1

A method of treating Fabry disease in an enzyme replacement therapy (ERT)-experienced patient diagnosed with Fabry disease and having mild renal impairment, the method comprising administering to the patient an effective amount of the migalastat or salt thereof at a frequency of once every other day, wherein the effective amount is 100 mg to 150 mg free base equivalent (FBE).
